exp3174 has been researched along with telmisartan in 11 studies
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (telmisartan) | Trials (telmisartan) | Recent Studies (post-2010) (telmisartan) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 1,930 | 480 | 1,038 |
| Protein | Taxonomy | exp3174 (IC50) | telmisartan (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.42 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0179 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.0003 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 0.5 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.2589 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.8621 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schieffer, B; Schmidt, B | 1 |
| Berellini, G; Cruciani, G; Mannhold, R | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Abad-Santos, F; Cabaleiro, T; López-Rodríguez, R; Novalbos, J; Ochoa, D; Prieto-Pérez, R; Román, M; Talegón, M; Wojnicz, A | 1 |
| Bauer, JH; Reams, GP | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| Dominiak, P; Häuser, W | 1 |
| Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J | 1 |
| Bähr, IN; Fleck, E; Fritzsche, J; Goebel, M; Gust, R; Hässle, PL; Kappert, K; Kaufmann, J; Kintscher, U; Ott, I; Stawowy, P; Tsuprykov, O; Unger, T | 1 |
| Arsenault, J; Cabana, J; Escher, E; Guillemette, G; Lanthier, L; Lavigne, P; Leduc, R; Lehoux, J | 1 |
3 review(s) available for exp3174 and telmisartan
| Article | Year |
|---|---|
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2 | 2003 |
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Pyridines; Quinolines; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 1995 |
1 trial(s) available for exp3174 and telmisartan
| Article | Year |
|---|---|
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Muscle Cells; PPAR gamma; Telmisartan; Tetrazoles | 2009 |
7 other study(ies) available for exp3174 and telmisartan
| Article | Year |
|---|---|
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles | 2005 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Topics: Alleles; Angiotensin Receptor Antagonists; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Female; Half-Life; Humans; Male; Polymorphism, Genetic; Reference Values; Sex Factors | 2013 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain | 2004 |
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Chlorocebus aethiops; COS Cells; Humans; Imidazoles; Inositol Phosphates; Irbesartan; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Threonine; Valine; Valsartan | 2010 |